CA9 and neoplasm: Furthermore, our results showing the ability of the specific CA IX/XII inhibitor SLC-0111 in sensitizing HNSCC cells and animal models to Cis-Pt in terms of reduced tumor growth and dissemination, highlight the possibility to use it as an integrated therapeutic approach to combat metastatic progression and overcome therapy resistance.